3 Australian Founder Led Growth Stocks To Own In October 2026

Global bond yields have surged to multi decade highs, pushing borrowing costs up and putting pressure on richly priced Australian growth stocks. That kind of stress often reveals which businesses have conviction from the inside, where founders and executives keep meaningful stakes and stay focused on long term value. This article highlights three fast growing Australian stocks with significant insider ownership that align with that theme.

The three fast growing stocks covered below are just a sample. The full Simply Wall St screen surfaces 113 more Australian companies where insider ownership and growth expectations combine into equally compelling narratives that are not detailed here.

If you want to identify and analyze those additional opportunities with the same lens, head straight into the Fast Growing Stocks With High Insider Ownership screener

PDI Gold (ASX:PDI)

PDI Gold is a West African gold producer focused on exploring, developing, mining and processing deposits around the Kiniéro Gold Mine in Guinea, with a market value of about A$5.0b that reflects investor attention on this high growth production and development story.

PDI Gold captures the screener theme neatly because its high insider alignment is tied to a single, fast expanding gold platform that has the potential to reshape future cash flows if execution keeps tracking to plan.

"The merger with Robex creates a larger platform with two producing mines and the Bankan development project, which can support higher group gold output over time and provide a broader base for revenue and earnings."

What happens to margins and cash generation if one key assumption in that growth path shifts even slightly in the opposite direction?

If that risk-reward balance has your attention, read the full narrative for PDI Gold to see how PDI Gold’s growth plans and insider alignment could react if assumptions start shifting.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals builds its whole story around precision radiopharmaceuticals, where late stage oncology candidates line up neatly with the screener’s focus on strong growth potential backed by confident insiders.

Telix Pharmaceuticals develops radiopharmaceutical diagnostics and therapies, anchored by precision medicine. This segment generated about $704 million of the roughly $891 million group total, with manufacturing contributing $277 million, and the business valued at about A$5.3b.

"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China, and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year (within their already upgraded guidance range)."

What really matters now is how one crucial clinical and regulatory swing factor plays out for that precision oncology platform.

That swing factor is exactly where the full narrative for Telix Pharmaceuticals pulls together how Telix Pharmaceuticals could accelerate, stall or quietly decouple from headline expectations.

Guzman y Gomez (ASX:GYG)

Guzman y Gomez runs a fast growing chain of Mexican quick service restaurants, where an aggressive rollout of company stores and franchises in Australia drives almost all of its A$551.8 million restaurant revenue and supports an A$2.4b market value.

Guzman y Gomez taps directly into the screener theme because its rapid restaurant rollout and high insider backing both lean into the same growth idea, and the digital engine behind that push is what makes the story especially interesting right now.

"GYG's operational investments in digital ordering, delivery partnerships, and a robust loyalty app (now 46% of network sales) position it to capture outsized market share among urban, time-pressed, and digital-first consumers."

What really determines how this growth story plays out is how one pressure on future profitability moves as the store network keeps expanding.

If that pressure on future profitability is what you care about, read the full narrative for Guzman y Gomez to see how Guzman y Gomez’s rollout could accelerate or stall.

Seeking Fresh Alternatives Before Momentum Flips

Fresh opportunities can move from quiet to flying quickly. Use that first mover edge before under the radar ideas get caught by the crowd.

• Spot resilient payers that may help steady portfolio income while prices swing by scanning the curated 3 dividend fortresses before yields start dropping.
• Track potential compounding machines hiding in plain sight and move before sentiment chases the 4 high quality undervalued stocks currently priced as if momentum never returns.
• Review real businesses linked to blockchain use cases while they are still under the radar for now by using the 18 cryptocurrency and blockchain stocks list.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com